Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 6/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2391124 | 0.92 | KMT2A (0.52) | HPGDKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL584306 | 0.92 | KMT2A (0.52) | HPGDKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL21994463 | 0.88 | HPGD (0.57) | HPGDKMT2AMEN1ALDH1A1RECQL | |
| SCHEMBL9938875 | 0.87 | HPGD (0.56) | HPGDKMT2AALDH1A1RECQLPTPN2 | |
| SCHEMBL8208172 | 0.86 | NR1H2 (0.46) | HPGDKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL22043078 | 0.85 | HPGD (0.49) | HPGDKMT2AMEN1ALDH1A1RECQL | |
| SCHEMBL4239798 | 0.82 | HPGD (0.57) | HPGDKMT2AMEN1ALDH1A1RECQL | |
| SCHEMBL337418 | 0.82 | ALDH1A1 (0.65) | HPGDKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL22051329 | 0.82 | HPGD (0.58) | HPGDKMT2AMEN1ALDH1A1RECQL | |
| SCHEMBL6105130 | 0.82 | HPGD (0.60) | HPGDKMT2AMEN1ALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041695-A1 | Thieno[2,3-b]pyridines as Potassium Channel Inhibitors | XENTION LIMITED (GB) | 2010-02-18 | — | — | US | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12384789-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2025149628-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF NICOTINAMIDE N-METHYL TRANSFERASE | ASTRAZENECA AB (SE) | 2025-07-17 | — | — | WO | disclosed |
| WO-2024263781-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2024-08-01 | — | — | US | disclosed |
| EP-3634953-B1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-01-03 | — | — | EP | disclosed |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | COGAN DEREK | 2007-06-21 | — | — | US | disclosed |
| US-7214802-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214802-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214802-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| CN-1930144-A | 3-'4-heterocyclyl -1,2,3,-triazol-1-yl!-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases | BOEHRINGER INGELHEIM PHARMA (US) | 2007-03-14 | — | — | CN | disclosed |
| WO-2007003960-A1 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007003962-A2 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| EP-1725544-A1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | US | disclosed |
| WO-2005090333-A1 | 3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | HPGD 2483/4885KMT2A 2628/4885MEN1 3923/4885 |
| US-20100041695-A1 | Thieno[2,3-b]pyridines as Potassium Channel Inhibitors | SCN8A, SCN1B, SCN2B | HPGD 2337/4885KMT2A 2561/4885MEN1 4162/4885 |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CDC7, CDK7, CDK17 | HPGD 1969/4885KMT2A 2341/4885MEN1 926/4885 |
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | TNF, IL6, IL1A | HPGD 58/4885KMT2A 4801/4885MEN1 4656/4885 |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | TNF, IL6, IL1A | HPGD 58/4885KMT2A 4801/4885MEN1 4656/4885 |
| US-12384789-B2 | Compounds for treating Huntington's disease | HTT, HYPK, FH | HPGD 220/4885KMT2A 1146/4885MEN1 1629/4885 |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | HPGD 2483/4885KMT2A 2628/4885MEN1 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.